MIRM Stock Analysis: Buy, Sell, or Hold?
MIRM - Mirum Pharmaceuticals, Inc. Common Stock
$96.31
-0.76 (-0.78%)
▼
5d:
-4.3%
30d:
-15.78%
90d:
-4.33%
HOLD
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When MIRM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: MIRM shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: MIRM shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: MIRM is currently trading at $96.31, which is considered oversold relative to its 30-day fair value range of $98.74 to $114.58. From a valuation perspective, the stock is trading at a discount (Forward PE: -277.8) compared to its historical average (185.2). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, MIRM is in a strong uptrend. The price is currently testing key support at $95.24. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MIRM scores 66/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $138.21 (+43.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, MIRM is in a strong uptrend. The price is currently testing key support at $95.24. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MIRM scores 66/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $138.21 (+43.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$98.74 -
$114.58
Company Quality Score
66/100
(BUY)
Options IV Signal
41th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
90.4%
Protect Your Profits
Holding MIRM? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 41th percentile)
- BULLISH: Strong technical setup (66/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 43.5% below Wall St target ($138.21)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Bottoming setup, but lagging the sector by 15% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$98.74 -
$114.58
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$9.31
(9.7%)
Support & Resistance Levels
Support Level
$95.24
Resistance Level
$104.66
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-277.79
Wall Street Target
$138.21
(+43.5%)
Revenue Growth (YoY)
37.9%
Profit Margin
-139.2%
PE vs Historical
-277.8 vs 185.2
CHEAP
Share & Embed Analysis
Last updated: August 23, 2026 6:32 AM ET
Data refreshes hourly during market hours. Next update: 7:32 AM
Data refreshes hourly during market hours. Next update: 7:32 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MIRM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Eric Bjerkholt
SELL
7287 shares
2026-03-16
Joanne Quan
SELL
7287 shares
2026-03-16
Jolanda Howe
SELL
4732 shares
2026-03-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 52 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$131 | 38 SELL |
Advanced MIRM Option Strategies
Professional options setups generated by AI based on today's MIRM price and gamma walls.
